Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation

Introduction: Crizotinib is a kinase inhibitor targeting c-MET/ALK/ROS1 used as the first-line chemical for the treatment of non-small cell lung cancer (NSCLC) with ALK mutations. Although c-MET is frequently overexpressed in 35-72% of NSCLC, most NSCLCs are primarily resistant to crizotinib treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Nan, You, Abin, Tian, Wei, Gu, Liankun, Deng, Dajun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415423/
https://www.ncbi.nlm.nih.gov/pubmed/32792859
http://dx.doi.org/10.7150/ijbs.45886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415423/
https://www.ncbi.nlm.nih.gov/pubmed/32792859
http://dx.doi.org/10.7150/ijbs.45886

Ejemplares similares